Since we have previously demonstrated that β4 depletion reduces the responsiveness of mammary tumor cells to TAM treatment, our data also suggest that a cooperative signaling between ErbB-3 and α6β4 integrin could influence resistance to hormone therapy in vivo. Here, ERBB3 is linked to breast cancer.